- Global Pharma News & Resources

Global Pre-Sterilized/Ready-to-Use Primary Packaging Market (2021 to 2030) - by Type of Packaging System, Packaging Material and Key Geography -

DUBLIN--(BUSINESS WIRE)--The "Pre-Sterilized/Ready-to-Use Primary Packaging Market: Focus on Cartridges, Syringes and Vials - Distribution by Type of Packaging System, Packaging Material and Key Geography, Industry Trends and Global Forecast, 2021-2030" report has been added to's offering.

This report features an extensive study of the current market landscape and future potential of ready-to-use primary packaging components, including cartridges, syringes and vials, and their respective closure systems (such as stoppers, needle shields and plungers) over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain.

Companies Mentioned

  • ABB
  • Afton Scientific
  • ALK Life Science Solutions
  • Allergy Laboratories
  • American Nurses Foundation
  • American Red Cross
  • AptarGroup
  • ARaymondlife
  • Aseptic Technologies
  • AST
  • Becton Dickinson
  • Berkshire Sterile Manufacturing
  • Bharat Rubber Works
  • Biomedical Advanced Research and Development Authority
  • BioPharma Solutions
  • Bormioli Pharma
  • Catalent
  • Centor
  • China Lemon Trading
  • And Many More Companies!

Key Questions Answered

  • Who are the prominent players engaged in the global pre-sterilized/ready-to-use primary packaging market?
  • What is the relative competitiveness of different ready-to-use primary packaging system manufacturers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the global ready-to-use primary packaging systems market?
  • What is the current, global demand for ready-to-use containers and closures?
  • What are the major market trends and driving factors that are likely to impact the growth of ready-to-use primary packaging systems market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Primary packaging, such as vials, syringes, and cartridges, and their affiliated closures, play a vital role in ensuring the stability, and sterility, and thereby, the overall quality, efficacy and safety of a drug product. Moreover, the packaging bears the product label, which provides information related to the drug and, in certain cases, dosing instructions. Pharmaceutical packaging is typically carried out under controlled conditions; specifically, for therapeutics that are designed for parenteral administration, fill/finish is carried out in sterile and aseptic environments. It is also crucial for innovators (or packaging service providers) to choose the appropriate, high quality primary packaging for their respective products; this is because the packaging material is in direct contact with the drug/therapy.

Building and maintaining the necessary expertise and infrastructure to support pharmacological fill/finish is a capital-intensive ordeal. Further, the growing complexity of modern pharmacological interventions, such as monoclonal antibodies, cell and gene therapies (which are typically produced in small batches) and the gradual (but imminent) shift to personalized therapies, has prompted drug developers to look for leaner manufacturing and packaging solutions. In this context, cost optimization is important and one of the available ways to save both time and capital is by bypassing manual processing and sterilization of primary packaging and switching to ready-to-use (RTU) formats.

Pre-sterilized RTU container-closure systems have gradually become very popular and are widely used in the modern pharmaceutical industry. As indicated earlier, such components significantly simplify the overall fill/finish process, primarily by eliminating the need for several additional steps (such as washing, drying and sterilization), which were previously required to prepare primary containers for filling. In other words, using RTU components helps improve operational efficiencies. Drug product manufacturers and fill/finish service providers claim that these off-the-shelf packing and closure systems, help them to better serve their clients in a timely and regulation-compliant manner. In this context, it is worth highlighting that RTU packaging systems were in high demand during the COVID-19 pandemic, when novel vaccines and experimental therapies needed to be produced and packaged for distribution in large quantities. The surge in demand for appropriate packaging solutions in adequate quantities, is likely to persist, significantly adding to the opportunity for RTU package and affiliated closure developers/suppliers. In future, as drug developers continue to strive to achieve greater flexibilities in their operations, we believe that the RTU packaging components market is likely to witness steady growth over the next decade.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for RTU primary packaging over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of these products, we have provided an informed estimate on the likely evolution of the market over the period 2021-2030. The report provides sales forecasts for the overall RTU primary packaging market, wherein both the current and upcoming opportunity is segmented across [A] type of packaging system (vials, syringes, cartridges and closures), [B] type of fabrication material used (glass and plastic) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Jul-2021